Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers*

Noninvasive tests of CYP3A enzymes

1994 • 414 citations

Carrier-mediated intestinal transport of drugs.

1996 • 394 citations

Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin

1992 • 373 citations

DRUG TREATMENT IN PSYCHIATRY

1964 • 372 citations

Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.

1990 • 324 citations

P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.

1996 • 266 citations

Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture

1992 • 263 citations

Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.

1995 • 199 citations

Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist

1992 • 182 citations

Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.

1993 • 157 citations

Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.

1996 • 157 citations

Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans.

1993 • 146 citations

Angiotensin II Receptor Inhibition

1996 • 116 citations

The mechanism of the warfarin-rifampin drug interaction in humans

1987 • 109 citations

Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography

1992 • 95 citations

Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.

1995 • 69 citations

Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP statusin vivo

1993 • 50 citations

The influence of rifampin treatment on caffeine clearance in healthy man

1995 • 33 citations

Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174*

1996 • 32 citations

Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections.

1994 • 19 citations

Ketoconazole does not effect the systemic conversion of losartan to E-3174.

1996 • 17 citations